In support of this notion, a CD8+ cell-mediated response directed against the AAV2 viral capsid (VP1) in association with hepatitis was reported in early trials of AAV2 when used as a vector for gene therapy17–19. This evidence concerns the gene CD8A and hepatitis A virus infection.